Evidence map›Paper›PMID 35444976›Full record

ArticleFrontiers in public health2022

Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India.

Jeromie Wesley Vivian Thangaraj, Muthusamy Santhosh Kumar, C P Girish Kumar, Pragya Yadav, D Sudha Rani, T Karunakaran, Manoj Murhekar

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jeromie Wesley Vivian ThangarajICMR-National Institute of Epidemiology, Chennai, India.
Muthusamy Santhosh KumarICMR-National Institute of Epidemiology, Chennai, India.
C P Girish KumarICMR-National Institute of Epidemiology, Chennai, India.
Pragya YadavICMR-National Institute of Virology, Pune, India.
D Sudha RaniICMR-National Institute of Epidemiology, Chennai, India.
T KarunakaranICMR-National Institute of Epidemiology, Chennai, India.
Manoj MurhekarICMR-National Institute of Epidemiology, Chennai, India.
National Institute of Epidemiology · INICMR-National Institute of Virology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

India witnessed a very strong second wave of coronavirus disease 2019 (COVID-19) during March and June 2021. Newly emerging variants of concern can escape immunity and cause reinfection. We tested newly diagnosed COVID-19 cases during the second wave in Chennai, India for the presence of Immunoglobulin G (IgG) antibodies to estimate the extent of re-infection. Of the 902 unvaccinated COVID-19 positive individuals, 53 (26.5%) were reactive for IgG antibodies and non-reactive for Immunogobulin M (IgM) antibodies. Among the 53 IgG-positive individuals, the interval between symptom onset (or last contact with the known case in case of asymptomatic) was <5 days in 29 individuals, ≥5 days in 11 individuals, while 13 asymptomatic individuals did not know their last contact with a positive case. The possible re-infections ranged between 3.2% (95% CI: 2.2-4.5%) and 4.3% (95% CI: 3.4-6.2%). The findings indicate that re-infection was not a major reason of the surge in cases during second wave. The IgG seropositivity among recently diagnosed unvaccinated COVID-19 patients could provide early indications about the extent of re-infections in the area.

Indexed as

COVID-19HumansImmunoglobulin GIndiaReinfectionReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2Immunoglobulin GCOVID-19genomic sequencingIgG antibodyreinfectionSARS-CoV-2

Identifiers

PMID35444976
PMCPMC9013836
OpenAlexW4225868963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.